Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas D James

Showing results (91-100 of 198) with videos related to

Pageof 20
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 26, 2013
Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarkerRichard Morgan, Richard T Bryan, Saqib Javed, et al.
BMJ Open|October 6, 2023
<b>CO</b>mparing Urolift and <b>S</b>tandard <b>T</b>ransurethral resection of prostate <b>A</b>head of <b>R</b>adiotherapy in men with urinary symptoms secondary to prostate enlargement in Southwest London and North Cumbria (CO-STAR): a study protocol for a randomised feasibility studyKathie Wong, Netty Kinsella, Jai Seth, et al.
JAMA Oncology|December 13, 2019
Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical TrialsSafae Terrisse, Eleni Karamouza, Chris C Parker, et al.
Plos One|September 3, 2015
Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder CancerMark O Kitchen, Richard T Bryan, Kim E Haworth, et al.
European Urology Oncology|May 30, 2025
Impact of Prostate Radiotherapy on Survival Outcomes in Patients with Metastatic Castration-sensitive Prostate Cancer: A Meta-analysis of Randomized Phase 3 Clinical TrialsSatı Coşkun Yazgan, Emre Yekedüz, Mutlay Sayan, et al.
BJU International|February 3, 2015
Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279)Amit Bahl, Susan Masson, Zafar Malik, et al.
Brain : a Journal of Neurology|March 20, 2016
Neuregulin-1 controls an endogenous repair mechanism after spinal cord injuryKatalin Bartus, Jorge Galino, Nicholas D James, et al.
Investigational New Drugs|April 29, 2014
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II studyYohann Loriot, Karim Fizazi, Robert J Jones, et al.
BMJ Oncology|January 31, 2025
Boosting and broadening recruitment to UK cancer trials: towards a blueprint for actionVeronica Nanton, Richard T Bryan, Anne M Pope, et al.
British Journal of Cancer|January 9, 2025
Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE studyJoe M O'Sullivan, Daniel Heinrich, Elena Castro, et al.
Pageof 20

Showing results (91-100 of 198) with videos related to

Sort By:
Pageof 20
European Journal of Cancer (Oxford, England : 1990)|February 26, 2013
Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarkerRichard Morgan, Richard T Bryan, Saqib Javed, et al.
BMJ Open|October 6, 2023
<b>CO</b>mparing Urolift and <b>S</b>tandard <b>T</b>ransurethral resection of prostate <b>A</b>head of <b>R</b>adiotherapy in men with urinary symptoms secondary to prostate enlargement in Southwest London and North Cumbria (CO-STAR): a study protocol for a randomised feasibility studyKathie Wong, Netty Kinsella, Jai Seth, et al.
JAMA Oncology|December 13, 2019
Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical TrialsSafae Terrisse, Eleni Karamouza, Chris C Parker, et al.
Plos One|September 3, 2015
Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder CancerMark O Kitchen, Richard T Bryan, Kim E Haworth, et al.
European Urology Oncology|May 30, 2025
Impact of Prostate Radiotherapy on Survival Outcomes in Patients with Metastatic Castration-sensitive Prostate Cancer: A Meta-analysis of Randomized Phase 3 Clinical TrialsSatı Coşkun Yazgan, Emre Yekedüz, Mutlay Sayan, et al.
BJU International|February 3, 2015
Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279)Amit Bahl, Susan Masson, Zafar Malik, et al.
Brain : a Journal of Neurology|March 20, 2016
Neuregulin-1 controls an endogenous repair mechanism after spinal cord injuryKatalin Bartus, Jorge Galino, Nicholas D James, et al.
Investigational New Drugs|April 29, 2014
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II studyYohann Loriot, Karim Fizazi, Robert J Jones, et al.
BMJ Oncology|January 31, 2025
Boosting and broadening recruitment to UK cancer trials: towards a blueprint for actionVeronica Nanton, Richard T Bryan, Anne M Pope, et al.
British Journal of Cancer|January 9, 2025
Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE studyJoe M O'Sullivan, Daniel Heinrich, Elena Castro, et al.
Pageof 20